2023 Lunar New Year Round-up: Biopharma in the APAC region
With the Lunar New Year ushering in celebrations for the pharmaceutical community around the world on Sunday January 22, 2023, we’ve rounded up some of the top CPHI Online articles and reports from the last year looking at pharmaceutical markets across the Asia-Pacific region.
Keep reading to see how the APAC pharmaceutical industry has fared in 2022, and how it is looking ahead to a new year as we leave the year of the tiger and enter the year of the rabbit (or the cat, depending on where you are)
Samsung Biologics to buy out Biogen’s stake in Samsung Bioepis
In January 2022, Samsung Biologics finalised an agreement to buy out Biogen’s stake in the Samsung Bioepis joint venture in January 2022. The deal will accelerate Samsung Bioepis’ biosimilar development capabilities and novel drug development performance. Samsung Biologics will continue to drive expansion in three core biopharmaceutical businesses – continued capacity enhancement, the establishment of growth opportunities in new business areas, and global expansion.
Chinese markets represents ‘single greatest generational opportunity’ for Pharma
The Chinese pharmaceutical market has been steadily changing from formerly generics-focused into an emphasis in innovation, driven in part by an aging population and government policies to meet these challenges. This article takes investigates the current biopharmaceutical economy in China, and key trends driving innovation.
Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwanese-based CDMO Bora Pharmaceuticals acquired niche generic drugs developer TWi Pharmaceuticals in an effort to expand their outsourced development and manufacturing services with increased capacity and manufacturing facilities. The acquisition marks a milestone in Bora’s history, enabling them to become the largest pharmaceutical group by volume in Taiwan.
The Korean biopharma market: Incentivizing innovation
Biopharmaceuticals in South Korea saw an unprecedented number of out-licensing deals and new drug approvals in the years leading up to 2022. However, the Korean biopharma market has yet to achieve commercial success of the same scale. We explore how the South Korean biopharmaceutical landscape and how drug innovation can be incentivised in a rapidly growing market in a framework dominated by out-licensing.
Thermo Fisher Scientific expands with state-of-the-art facility in China
A new state-of-the-art cGMP facility is now open in China as part of Thermo Fisher Scientific’s efforts to address the needs of companies and provide quicker access to therapies for patients in China and the APAC region. The facility offers integrated clinical and commercial drug type capabilities and process development through to sterile fill-finish. Thermo Fisher has announced plans to expand these capabilities to commercial packaging and labelling.
Lonza start commercial operations in newly expanded facility
Lonza Small Molecules have expanded their API manufacturing facility in Nansha, China to enable smoother transitions between small and large-scale manufacturing. The expansion includes manufacturing equipment to span the gap between early- and late-phase production.
Related News
-
News Sai Life Sciences opens new HPAPI manufacturing facility in Bidar, India
A new HPAPI development and manufacturing block is now open at Sai Life Sciences’ Bidar Manufacturing Campus, expanding the CRDMO’s capabilities in small molecule discovery and commercialisation. -
News Samsung Biologics Awarded the Terra Carta Seal for Ensuring a Sustainable Future
Samsung Biologics has been awarded The Terra Carta Seal from the sustainable markets initiative. -
News Anima Biotech brings mRNA biology modulators to AbbVie against oncology and immunology targets
A USD $42 million collaboration between AbbVie and Anima Biotech aims to leverage the latter’s mRNA Lightning technology platform to enhance therapeutic development programs in oncology and immunology. -
News A United Cause: strategic partnership between BioNTech and the Government of the UK announced
A multi-year collaboration between BioNTech and the Government of the United Kingdom will see the expansion of the company’s presence in the UK, focusing on areas like cancer immunotherapies and infectious disease vaccines. -
News CordenPharma signs billion dollar agreement to manufacture new peptide
CordenPharma, the CDMO specialising in APIs, lipid excipients, and drug products, signs a new billion dollar contract to expand its manufacturing capabilities. -
News Algorithm accelerated: machine-learning may reduce drug formulation development times
Machine-learning models demonstrate the potential to accelerate drug formulation discovery and development for long-acting injectables. -
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance